Online inquiry

IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5431MR)

This product GTTS-WQ5431MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD74 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001025158.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 972
UniProt ID P04233
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ5431MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11822MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MK-4280
GTTS-WQ5689MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ9969MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA KBSA301
GTTS-WQ6973MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ETI-204
GTTS-WQ13967MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ9603MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ983MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-368
GTTS-WQ4283MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIIB-054
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW